logo
  Join        Login             Stock Quote

Dendreon (DNDN) Sells New Jersey Facility To Novartis (NVS) Unit

 December 20, 2012 10:48 AM
 


(By Balaseshan) Dendreon Corp. (NASDAQ: DNDN) said it has sold its immunotherapy manufacturing facility (IMF) based in Morris Plains, New Jersey to Novartis Pharmaceuticals Corp., the U.S. pharmaceuticals unit of Swiss drug giant Novartis AG (NYSE: NVS), for $43 million in cash.

Dendreon's Morris Plains, New Jersey, facility is a 173,100 square foot IMF, featuring capabilities to manufacture Provenge (sipuleucel-T).

Provenge is the first autologous cellular immunotherapy to receive U.S. Food and Drug Administration approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

[Related -Jobs Growth Tepid At Best]

"Dendreon continues to make progress in improving our financial strength, and this transaction is aligned with that goal as we work to build value for our shareholders," said John Johnson, chairman, president and chief executive officer of Dendreon.

Earlier this year, Dendreon announced its intent to wind down the manufacturing of Provenge at the Morris Plains facility in conjunction with a strategic restructuring plan designed to accelerate the company's path to profitability and future growth.

"We are also pleased that approximately 100 of the existing employees at the facility will have the opportunity to retain their jobs and work for Novartis as the company builds out its immunotherapy operations and develops new treatments for patients," said Johnson.

[Related -Futures Down As Market Awaits Economic Data; Research In Motion Ltd. (BBRY) Plunges]

The safety evaluation of Provenge was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis. The most common adverse events (incidence greater-than or equal to 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache.

In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the Provenge group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the Provenge group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of about 1500 patients to further evaluate a small potential safety signal of cerebrovascular event.

DNDN is trading up 0.75% at $5.38 on Thursday. The stock has been trading between $3.69 and $17.04 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.